$ACT Company News

New Post Public Reply Private Reply Replies (0) Message Board

May 15, 2014 at 11:51 AM

$ACT Company News

Pfizer's plan to relocate after merger deal draws lawmakers' fire

11:30 a.m. May 9, 2014
- blogs.marketwatch.com

Corner drug store may move overseas to save on taxes
6:30 a.m. April 16, 2014
- Al Lewis

Intuitive Surgical slumps; Facebook extends rally
3:41 p.m. April 9, 2014
- Saumya Vaishampayan

Actavis acquires Silom Medical for $100 million
10:19 a.m. April 1, 2014
- MarketWatch.com

The 10 most overbought stocks in the S&P 500 index
12:19 p.m. March 25, 2014
- The Trading Deck

UK drug rejection, patent concerns take a bite out of Celgene shares

1:33 p.m. March 14, 2014
- blogs.marketwatch.com

Mylan to start selling generic Celebrex in May
7:22 a.m. March 13, 2014
- MarketWatch.com

Pfizer loses Celebrex patent ruling; shares halted but effect muted

3:21 p.m. March 12, 2014
- blogs.marketwatch.com

Staples awash in red; eBay up as Icahn posts new letter
4:09 p.m. March 6, 2014
- Victor Reklaitis

Icahn Enterprises reports profit up 144% in 2013
10:22 a.m. March 3, 2014
- MarketWatch

Citadel hedge fund’s recent moves
11:12 a.m. Feb. 25, 2014
- Insider Monkey

Stocks rally; S&P 500 ends right below record
4:45 p.m. Feb. 24, 2014
- Victor Reklaitis

U.S. stock market is starting to ride a tech M&A wave
5:31 a.m. Feb. 24, 2014
- Wallace Witkowski

Actavis continues hot streak with better-than-expected earnings

11:21 a.m. Feb. 20, 2014
- blogs.marketwatch.com

Actavis swings to loss on charges, write-downs
8:03 a.m. Feb. 20, 2014
- MarketWatch.com

Pharma megamergers bring higher profits, better returns, study says

1:59 p.m. Feb. 19, 2014
- blogs.marketwatch.com

Actavis, Forest shares continue their climb in aftermath of $25 billion deal

11:03 a.m. Feb. 19, 2014
- blogs.marketwatch.com

U.S. stocks edge up; Nasdaq gains for 8th day in a row
4:38 p.m. Feb. 18, 2014
- Anora Mahmudova

Forest Laboratories, Actavis surge on buyout deal
4:10 p.m. Feb. 18, 2014
- Ben Eisen

S&P 500, Nasdaq extend win streaks but Dow dips: stock market live blog recap

4:06 p.m. Feb. 18, 2014
- blogs.marketwatch.com

Actavis extends marketing agreement

9:32 a.m. Today9:32 a.m. May 15, 2014
- Seeking Alpha

Lilly loses Alimta patent case in U.K. to Actavis

8:56 a.m. Today8:56 a.m. May 15, 2014
- Seeking Alpha

Lilly Says Court Rules in Favor of Generic Maker on Alimta

6:44 a.m. Today6:44 a.m. May 15, 2014
- The Wall Street Journal Interactive Edition

New leadership team at Actavis after Forest deal closes

9:56 a.m. May 14, 2014
- Seeking Alpha

Forest Labs' Saunders to Head Actavis When Deal Closes

8:55 a.m. May 14, 2014
- The Wall Street Journal Interactive Edition

Cross-Border Megamergers Drive Global Takeover Boom

4:01 p.m. May 12, 2014
- Investors Business Daily

3 Drugs Stocks On The Rise

1:02 p.m. May 12, 2014
- TheStreet.com

Actavis and Valeant settle patent fight

8:26 a.m. May 12, 2014
- Seeking Alpha

The 'Inversion' Premium

7:29 p.m. May 11, 2014
- The Wall Street Journal Interactive Edition

Vivus Discloses Competitive Threat

10:51 a.m. May 10, 2014
- Seeking Alpha

M.D. Sass: Bullish on Broadcast, Health Care

3:26 a.m. May 10, 2014
- Barrons.com

Acorda Misses on Earnings, Beats Revs - Analyst Blog

1:43 p.m. May 7, 2014
- Zacks.com

3 Drugs Stocks Dragging The Industry Down

1:03 p.m. May 7, 2014
- TheStreet.com

What Does Celgene's May 15 Markman Hearing Mean to You?

10:11 a.m. May 7, 2014
- TheStreet.com

Actavis, Michael Kors Among World Stocks Near Buy Points

5:50 p.m. May 6, 2014
- Investors Business Daily

10-Q: ACTAVIS PLC
5:15 p.m. May 5, 2014
- Edgar Online - (EDG = 10Q, 10K)

Hottest Healthcare Stocks Now – HMSY ACAD ACT MWIV

1:45 p.m. May 5, 2014
- InvestorPlace.com

Best Five Stocks Over $100
10:07 a.m. May 3, 2014
- 247WallSt.com

AstraZeneca Nixes New Bid As Pfizer Woos British PM

1:11 p.m. May 2, 2014
- Investors Business Daily

Earnings Beat at Endo, Shares Up on Improved Outlook - Analyst Blog

12:10 p.m. May 2, 2014
- Zacks.com

Actavis Extends Exclusive Agreement to Distribute Authorized Generic Concerta®
8:45 a.m. Today8:45 a.m. May 15, 2014
- PR Newswire - PRF

Actavis Announces Proposed Senior Leadership Team Effective Following Completion of Forest Laboratories Acquisition
8:00 a.m. May 14, 2014
- PR Newswire - PRF

Agreements, Earnings Releases, Senior-Level Retirements and Appointments, and Marketing Authorizations - Analyst Notes on Actavis, Jazz Pharmaceuticals, Bristol-Myers, Biogen Idec and AbbVie
7:00 a.m. May 14, 2014
- PR Newswire - PRF

Actavis Receives Final Approval for Generic Version of Exalgo®
5:00 p.m. May 13, 2014
- PR Newswire - PRF

Actavis to Present at Sanford C. Bernstein Thirtieth Annual Strategic Decisions Conference 2014
4:45 p.m. May 13, 2014
- PR Newswire - PRF

Actavis Announces Acanya® Gel Patent Challenge Settlement
8:00 a.m. May 12, 2014
- PR Newswire - PRF

Technical Coverage on Pharma Equities -- Research on Allergan, Actavis, Medicines Co., and Akorn
11:30 a.m. May 9, 2014
- PR Newswire - PRF

Actavis Launches Generic Version of Catapres-TTS®
4:05 p.m. May 7, 2014
- PR Newswire - PRF

Financial Results, Study Results, and Conference Schedules - Analyst Notes on Actavis, BMS, Baxter, Biogen Idec and AbbVie
9:00 a.m. May 6, 2014
- PR Newswire - PRF

Actavis and Forest Announce Effectiveness of Registration Statement
on Form S-4
9:02 a.m. May 5, 2014
- BusinessWire - BZX

Actavis and Forest Announce Effectiveness of Registration Statement on Form S-4
9:00 a.m. May 5, 2014
- PR Newswire - PRF

Pfizer Expects $100 Billion Grab for AstraZeneca to Boost Pipeline
and Drop Tax Rate, an Industrial Info News Alert
6:31 a.m. April 30, 2014
- Marketwire

Stocks Close to Reporting their Earnings -- Research on Actavis, NYSE Community Bancorp, Hess, and Dominion Resources
4:36 a.m. April 30, 2014
- PR Newswire - PRF

Actavis Sues FDA Regarding Delay of Generic Celebrex® Approval
5:14 p.m. April 28, 2014
- PR Newswire - PRF

Strategic Collaborations, Fresh Agreements, and Upcoming Conferences - Analyst Notes on Biogen, Bristol-Myers, AbbVie, Actavis and Bard
8:00 a.m. April 28, 2014
- PR Newswire - PRF

Stockholder Rights Plan, Quarterly Results, Clinical Trial Results, Purchase Agreements, and New Contracts - Analyst Notes on Allergan, Gilead, Pfizer, Actavis and Express Scripts
8:00 a.m. April 25, 2014
- PR Newswire - PRF

Actavis Announces Celebrex® Patent Challenge Settlement
9:20 a.m. April 24, 2014
- PR Newswire - PRF

Actavis Announces Departure of G. Frederick Wilkinson, President, Actavis Global R&D
9:03 a.m. April 21, 2014
- PR Newswire - PRF

Actavis to Acquire Four Products from Akorn
4:15 p.m. April 17, 2014
- PR Newswire - PRF

Actavis and Forest Laboratories Receive FTC Second Request Under Hart-Scott-Rodino
4:05 p.m. April 17, 2014
- PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Altea Targets US Market, Appoints Rodrick VP Amid Expansion

Wading into the murky waters of U.S. healthcare insurance isn't for the faint of heart, but Altea's making its move. Backed by MISSION, they're banking on a niche strategy by tapping veteran Justin Rodrick as Vice President. Their tactic? Aim squarely at the under-served segment of small to mid-sized medical and healthcare facilities. The play's bold, and if Rodrick's got...

Navigating Home Care: What Families Need to Know

Peeking into the Home Care Playbook The process of starting home care isn't some mind-boggling puzzle. For families in Northeastern Pennsylvania, things kick off with a cordial chinwag with a care coordinator—no paperwork chains or Kafkaesque contracts right off the bat. Now, if you've got someone in need of care, this gives you time to shove all your questions onto the...

Innovative Trial Targets Drug Resistance in Lung Cancer

The Battle Against Drug Resistance Heats Up Folks, we're in a never-ending fight here against one of the toughest adversaries out there: lung cancer. And lemme tell ya, when drugs show resistance, it's like trying to punch a ghost. But there’s a fresh wind blowing, as Dr. Bobak Parang steps up to the plate with a $620K grant aimed squarely at tackling drug resistance in...

Kimberly-Clark Extends Kenvue Notes Exchange Deadline

Deadline Extended for Kenvue's Noteholders In the wild world of corporate finance, the only thing more unpredictable than the weather is a boardroom decision. Kimberly-Clark (NASDAQ: KMB) just threw one such curveball by extending the deadline on their exchange offers for Kenvue Notes to November 2, 2026. Seems like 5 p.m. New York time is the new witching hour for this...

Epilepsy Market's Explosive Growth Forecasted to 2036

It's a wild world out there for epilepsy treatments—like a relentless bull run with everyone eyeing the prize. The latest buzz points to a fat 2036 forecast for this sector, driven by a mix of standout technologies and breakthrough therapies. You'd be a fool to blink and miss it. Rising Numbers Stir the Market The numbers, oh boy, they're climbing. In 2025, about 7...

Don Silvestri: NFL Vet's Service Legacy Continues

More Than Just a Debt Guru It's not every day you see a former NFL player shifting gears so smoothly into the corporate world, and then to community service like a missile lock. But that's exactly what Don Silvestri, president of Debt.com, has done. Dragging a hefty reputation as a placekicker for teams like the New York Jets and the Buffalo Bills, he's now making...

CORE Embraces Tech to Boost Organ Donation Efforts

Innovation Meets Organ Donation Out of all the business moves you hear about, this one rings loud because it doesn’t just move the needle on a spreadsheet—it moves the needle on life or death. The Center for Organ Recovery & Education (CORE) is stepping into the future with a high-tech touch to enhance their lifesaving mission. Partnering with InVita Healthcare...

MillerKnoll's 3D Push: Legacy Meets Innovation

Bringing the Classics to the Digital Frontier Here's what's lighting a fire under the world of high-end furniture: MillerKnoll's got its eye on the prize by jazzing up Knoll.com with shiny new 3D product configurators. It's like taking a century's worth of design stuffiness and spinning it into the future, ready to dazzle a whole new set of eyeballs. Why This Move Matters...

Dotwork's AI Leap: Acquires Arcario to Revolutionize Strategy

Transformations in enterprise management are knocking at the door with Dotwork's latest move. Their strategic acquisition of Arcario Group aims to flip the lid on how companies tie strategies to their daily grind using AI. Let me level with you—this ain't about just spicing up some dashboards or workflows. We're talking about an enterprise-level overhaul in the very way...

Boeing's Third Quarter 2026: Progress Amid Losses

Boeing's Rocky Rollercoaster Ride This Quarter Man, if you want a case study on turbulence in the business world, look no further than Boeing's recent third-quarter performance. This juggernaut managed to clock in $24.2 billion in revenues, up 4% from last year, but it still can't seem to shake off its streak of red ink. We're talking a net loss of $116 million, or a GAAP...